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RESEARCH ARTICLE
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Center for Vaccine Development, National School of Tropical Medicine, Houston, Texas, United States of
America, 3 Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas
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Abstract
Background
The Brugia malayi Bm-103 and Bm-RAL-2 proteins are orthologous toOnchocerca volvulus
Ov-103 andOv-RAL-2, and which were selected as the best candidates for the develop-
ment of an O. volvulus vaccine. The B.malayi gerbil model was used to confirm the efficacy
of theseOv vaccine candidates on adult worms and to determine whether their combination
is more efficacious.
Methodology and Principle Findings
Vaccine efficacy of recombinant Bm-103 and Bm-RAL-2 administered individually, concur-
rently or as a fusion protein were tested in gerbils using alum as adjuvant. Vaccination with
Bm-103 resulted in worm reductions of 39%, 34% and 22% on 42, 120 and 150 days post
infection (dpi), respectively, and vaccination with Bm-RAL-2 resulted in worm reductions of
42%, 22% and 46% on 42, 120 and 150 dpi, respectively. Vaccination with a fusion protein
comprised of Bm-103 and Bm-RAL-2 resulted in improved efficacy with significant reduction
of worm burden of 51% and 49% at 90 dpi, as did the concurrent vaccination with Bm-103
and Bm-RAL-2, with worm reduction of 61% and 56% at 90 dpi. Vaccination with Bm-103
and Bm-RAL-2 as a fusion protein or concurrently not only induced a significant worm
reduction of 61% and 42%, respectively, at 150 dpi, but also significantly reduced the fecun-
dity of female worms as determined by embryograms. Elevated levels of antigen-specific
IgG were observed in all vaccinated gerbils. Serum from gerbils vaccinated with Bm-103
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and Bm-RAL-2 individually, concurrently or as a fusion protein killed third stage larvae in
vitro when combined with peritoneal exudate cells.
Conclusion
Although vaccination with Bm-103 and Bm-RAL-2 individually conferred protection against
B.malayi infection in gerbils, a more consistent and enhanced protection was induced by
vaccination with Bm-103 and Bm-RAL-2 fusion protein and when they were used concur-
rently. Further characterization and optimization of these filarial vaccines are warranted.
Author Summary
Onchocerciasis and Lymphatic filariasis (LF) are debilitating neglected tropical diseases
(NTDs). Practical challenges in implementation of mass drug administration (MDA) such
as prolonged treatment regime requirements and the possible emergence of drug resis-
tance will likely impede the elimination of these NTDs. Hence, the availability of an effica-
cious prophylactic vaccine would be an invaluable tool. The objective of the present
studies was to use the B.malayi-gerbil model of filariasis as a surrogate system to test the
efficacy of filarial molecules as vaccine targets for an onchocerciasis vaccine. The vaccine
efficacy of Onchocerca volvulus recombinant proteins Ov-RAL-2 and Ov-103 was recently
demonstrated using a mouse diffusion chamber model. In this communication, we pro-
vide encouraging results on the vaccine efficacy of Bm-RAL-2 and Bm-103, individually or
in combination. Our data demonstrate that vaccination with Bm-RAL-2 and Bm-103 con-
currently and as a fusion protein confers not only a consistent and significant protection
against B.malayi infection in gerbils, but also reduces the fecundity of female worms as
demonstrated in embryogram analyses. Our results support the contention that Ov-RAL-2
and Ov-103 are excellent onchocerciasis vaccine candidates and that further investigations
leading to their development as a vaccine are warranted.
Introduction
Onchocerciasis is an important neglected tropical disease (NTD) caused by the filarial parasite,
Onchocerca volvulus. The parasite is transmitted by black fly species of the genus Simulium and
is found in some regions of South and Central America but most commonly now in sub-Saha-
ran areas of Africa. The Global Burden of Disease Study 2013 estimates that 16.96 million peo-
ple are infected with O. volvulus [1]. It is a leading cause of blindness in Africa and produces
severe skin disease and generalized morbidity in some individuals. Annual MDA programs
using ivermectin to eliminate microfilaremia and reduce transmission have been effective in
some areas and the elimination of O. volvulus has been targeted for 2025 by the African Pro-
gramme for Onchocerciasis Control (APOC) [2]. Such activities have reduced the global preva-
lence of onchocerciasis by 31.2% over the last two decades [1]. Nonetheless, practical
challenges have arisen that will likely impede the successful elimination of onchocerciasis in
the planned time line. These include the need for repeated ivermectin treatment regime for
many years [3], and the possible emergence in some endemic areas of resistance to ivermectin
[4–8]. In addition, MDA cannot be implemented in areas where onchocerciasis and loiasis are
co-endemic because ivermectin treatment of patients with high Loa loamicrofilaremia may
lead to severe adverse side effects including encephalopathy [9]. According to a new APOC
Vaccine Efficacy of Bm-103 and Bm-RAL-2
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004586 April 5, 2016 2 / 26
Competing Interests: The authors have declared
that no competing interests exist.
estimate, elimination would require an estimated 1.30 billion treatments, lasting until 2045
[10]. However, a recent survey of almost 400 NTD experts indicated that many believe oncho-
cerciasis will never be eliminated through MDA with ivermectin solely [11]. Hence, to
strengthen the current elimination programs additional tools are necessary to prevent infec-
tion, cure infection and interrupt transmission, and thus complement current MDA programs
[12–14]. An efficacious vaccine against onchocerciasis will be an invaluable tool in the effort to
eliminate onchocerciasis from humans.
Immunity to filarial infections has been well documented in animal models for onchocercia-
sis and lymphatic filariasis (LF). For onchocerciasis, the mouse diffusion chamber model serves
as an efficient method for identifying candidate vaccine antigens and studying protective
immunity against the early stages of infection with the third-stage larvae (L3) of O. volvulus.
Lange et al., 1993 reported a significant reduction in the survival of challenge parasites when
mice are vaccinated with irradiated O. volvulus L3s [15]. Similarly, it was observed in cattle in
natural infection settings where irradiated L3s induced protective immunity to O. ochengi, a
closely related parasite [16]. In LF animal models, vaccination with irradiated L3s has also been
demonstrated to be effective in permissive hosts of Brugia species such as cats, dogs, and Mon-
golian gerbils [17]. Many investigators have also shown some protective vaccine efficacy with a
wide range of native and recombinant proteins of O. volvulus and B.malayi (as reviewed in
[17]).
The absence of a permissive small animal model of onchocerciasis, which allows for the
complete development of O. volvulus parasites, prompted us to utilize at least two complemen-
tary animal models which provide distinct advantages for validating vaccine candidates before
moving forward to clinical development. This strategy is discussed in detail elsewhere [4, 14,
18]. The O. volvulus–mouse diffusion chamber model allows testing vaccines only against the
L3-L4 stages of the parasite and the in depth study of the murine effector mechanisms within
the confined environment of the diffusion chamber. While the B.malayi-Mongolian gerbil
model lacks the availability of immunological reagents and genetically defined animals when
compared with the mouse system, it does allow for the testing of vaccines in a completely per-
missive host, which allows for examining efficacy against all life cycle stages of the parasite
including effects on the normal development of embryogenesis. Together, these two models
provide a rigorous testing of homologous protein vaccines. The objective of the studies
reported in the current paper is to show that the B.malayi–gerbil model of lymphatic filariasis
validates the positioning of the two selected recombinant O. volvulus vaccine proteins, Ov-103
and Ov-RAL-2 [19], for a prophylactic anti-Onchocerca vaccine. Ov-RAL-2 was identified by
screening an adult stage cDNA library with anti-L3 rabbit serum [20, 21], and Ov-103 was
identified by screening an adult stage cDNA library with antiserum from O. volvulus infected
chimpanzee [22].
In the current study, we tested the efficacy of Bm-103 and Bm-RAL-2, the homologs of the
proven vaccine candidates of O. volvulus, Ov-103 and Ov-RAL-2, in the Mongolian gerbil
model either individually, as a fusion protein or as concurrent vaccines with separate injec-
tions. Bm-103 and Bm-RAL-2 induced protection against B.malayi infection in Mongolian
gerbils. Higher levels of protection were achieved when gerbils were vaccinated with Bm-103
and Bm-RAL-2 concurrently or as a fusion protein. Vaccination with Bm-RAL-2, Bm-103 and
Bm-RAL-2 concurrently or as a fusion protein also reduced the fecundity of female worms
recovered at 150 dpi as demonstrated by embryograms. Using the B.malayi infection model,
we have confirmed the effectiveness of the O. volvulus orthologous antigens from B.malayi,
Bm-103 and Bm-RAL-2, as efficacious vaccines also against infection with B.malayi L3s. More-
over, the present studies have also established that Bm-103 and Bm-RAL-2 could also be con-
sidered as validated vaccines to prevent LF.
Vaccine Efficacy of Bm-103 and Bm-RAL-2
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Materials and Methods
Expression and purification of B.malayi vaccine antigens
Bm-103. Bm-103 (GenBank accession # XP_001891826) is a homolog of Ov-103 in Brugia
malayi with 68% amino acid sequence identity. The amino acid sequence comparison between
Bm-103 and Ov-103 and the phylogenetic analysis of Bm-103 with other nematode homologs
are shown as supplementary figures (Fig S1 A–B in S1 Dataset). Even though there is no spe-
cific functional domain found in Bm-103 through Pfam database search, in previous studies
the O. volvulus homolog Ov-103 was initially described as a microfilariae surface associated
antigen [22]. In later studies, it was found to be also expressed by O. volvulus L3s [23], and vac-
cination with recombinant Ov-103 induced strong protective immunity in O. volvulusmouse
chamber model [19]. Recent immunoelectron microscopy studies were used to localize Bm-
103 and Ov-103 in B.malayi and O. volvulus, respectively, using monospecific human anti-Ov-
103 antibodies [24] that cross reacted with the Bm-103 protein. In O. volvulus, Ov-103 was con-
firmed to be localized in the hypodermis and cuticle of adult female worms, and on the surface
of MF [22], but it also now newly shown that it is localized on the surface and the glandular
esophagus of L3s (Fig S2 in S1 Dataset). Similarly, Bm-103 was found to be localized in the
hypodermis and cuticle of adult female worm, L3 and MF (Fig S2 in S1 Dataset).
The DNA coding for Bm-103 without the C-terminal transmembrane domain was codon
optimized and then synthesized by GenScript (Piscataway, NJ, USA) and subcloned in-frame
into the yeast expression vector pPICZαA (Life Technologies, Carlsbad, CA, USA) with EcoRI/
XbaI sites. Recombinant Bm-103 with 6xHis-tag at the C-terminus was expressed in Pichia pas-
toris X-33 under induction with 0.5% methanol and purified with immobilized metal affinity
chromatography (IMAC) as described previously [19], [25]. Bm-103 is shown on a SDA-PAGE
gel stained with Coomassie Blue with molecular weight of 14.5 KDa (Fig 1).
Bm-RAL-2. The B.malayi, Bm-RAL-2 (GenBank accession# XP_001900036) is a homolog
of Ov-RAL-2 with an amino acid identity of 62%. The amino acid sequence comparison
Fig 1. SDS-PAGE of purified Brugia malayi recombinant proteins,Bm-RAL-2, Bm-103 and Bm-RAL-2
—Bm-103 fusion protein. Two μg of each protein was loaded in SDS-PAGE along with SeeBlue pre-stained
protein marker (Invitrogen, USA). (A) Bm-RAL-2; (B) Bm-103; (C) Bm-RAL-2—Bm-103 fusion protein.
doi:10.1371/journal.pntd.0004586.g001
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between Bm-RAL-2 and Ov-RAL-2 and the phylogenetic analysis of Bm-RAL-2 with other
nematode homologs are shown as supplementary figures (Fig S3 A–B in S1 Dataset). Ov-RAL-
2 was first shown to be a surface antigen in O. volvulus adult worm [20, 21] that induced pro-
tective immunity in an O. volvulusmouse model [19]. Pfam database search found it contained
a DUF148 domain with unknown function. Immunoelectron microscopy studies were used to
localize Bm-RAL and Ov-RAL in B.malayi and O. volvulus, respectively, using monospecific
human anti-Ov-RAL-2 antibodies [24] that cross reacted with the Bm-RAL-2 protein. In O.
volvulus, Ov-RAL-2 was not only localized in the hypodermis and cuticle of adult female worm
as previously shown, but also to the surface of L3 larvae and MF as well as the glandular esoph-
agus of L3s (Fig S4 in S1 Dataset). Similarly, Bm-RAL-2 was found to be localized in the hypo-
dermis and cuticle of adult female worm, but it also newly shown that it is localized to the
surface of L3 larvae and MF as well as the glandular esophagus of L3s (Fig S4 in S1 Dataset).
The DNA coding for Bm-RAL-2 without signal peptide was synthesized by GenScript (Pis-
cataway, NJ, USA) and subcloned in-frame into Escherichia coli expression vector pET41a
(EMDMillipore, Billercia, MA, USA) with the fusion GST deleted (NdeI/XhoI). Recombinant
Bm-RAL-2 with 6xHis-tag at C-terminus was expressed under induction of 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) and purified with IMAC as described previously [19], [26].
Bm-RAL-2 is shown on a SDA-PAGE gel stained with Coomassie Blue with molecular weight
of 16 KDa (Fig 1).
Bm-103 –Bm-RAL-2 fusion protein. The Bm-103 and Bm-RAL-2 proteins were expressed
as a fusion protein to study the protection of these two recombinant proteins in combination. The
coding regions of Bm-103 and Bm-RAL-2 were fused using a flexible linker present in theNecator
americanus proteinNa-ASP-1 and which was shown by structural analyses to connect the two
pathogenesis-related (RP) domains [25, 27]. The linker has no specific function but facilitates flex-
ible hanging of the two pathogenesis-related domains and hence was chosen to connect Bm-103
and Bm-RAL-2 in this study. The fusion recombinant plasmid DNAwas cloned into E. coli
expression vector pET41a (EMDMillipore, USA) with GST knockout and recombinant fusion
protein was expressed and purified as described above. The expressed Bm-103 –Bm-RAL-2 fusion
protein had a correct predicted molecular weight of 36 KDa based on the protein sequence with
some small molecular weight degraded bands (Fig 1). Based on deduced amino acid sequences,
the Bm-103 –Bm-RAL-2 fusion protein has 60% identity with the protectiveOv-103 –Ov-RAL-2
fusion protein [19]. The amino acid sequence alignment of fusion proteins, Bm-103 –Bm-RAL-2
andOv-103 –Ov-RAL-2 are shown as supplementary figures (Fig S5 in S1 Dataset).
Ethics statement
Animals were handled according to the NIH guidelines for animal experimentation and the
animal experimental protocols were approved by the Louisiana State University Institutional
Animal Care and Use Committee under the protocol number: 12–037. The animal care and
use protocol adhered to the “Guide for the Care and Use of Laboratory Animals (the Guide)”
published by the National Research Council, USA.
Animals and parasites
Eight to ten week old male Mongolian gerbils (Meriones unguiculatus) (Charles River, USA)
were used in all the vaccination experiments. Animals were housed in cages containing wood
shaving bedding with 5 gerbils per cage. They were fed autoclavable rodent chow and given
water ad libitum. Cages were kept in animal housing rooms in Louisiana State University
School of Veterinary Medicine (LSU-SVM) that were pathogen-free with controlled tempera-
ture, humidity and light cycle conditions. The life cycle of B.malayi is being maintained at the
Vaccine Efficacy of Bm-103 and Bm-RAL-2
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LSU-SVM using Mongolian gerbils as the definitive host for the parasite and the Black Eyed
Liverpool strain of Aedes aegypti as the intermediate host and vector. B.malayi L3 were recov-
ered from infected mosquitoes on day 14 post blood meal using the previously described Baer-
mann technique [28]. In two experiments (5 and 9, Table 1), the B.malayi L3s were obtained
from Filariatech Inc, Athens, Georgia, USA. The L3s from this source are used by many investi-
gators and the recoveries from gerbils inoculated with these L3s are comparable with those
obtained when we were using L3s from our own colony. The L3s from Filariatech were pro-
duced by feeding A. aegypti on microfilareamic cats and harvested using the Baermann tech-
nique as described above. L3s were shipped in 50 ml falcon tubes containing RPMI medium at
room temperature via an overnight express courier service from Athens, GA to LSU-SVM.
Once received, L3s were washed three times with fresh RPMI medium and then used immedi-
ately for SC infection.
Experimental protocol for vaccination and L3 challenge
Multiple vaccination experiments were performed using recombinant Bm-103, Bm-RAL-2,
Bm-103—Bm-RAL-2 fusion protein and with concurrent injection of both alum-formulated
proteins but in separate sites (concurrent; Bm-103 + Bm-RAL-2). Necropsies were performed
at different time points depending on the objective of the study. All the vaccination experi-
ments consisted of at least 2 groups, an antigen vaccinated group(s) and an adjuvant control
group with 10 animals in each group. Alum was used in all cases as the adjuvant, and the anti-
gen-adjuvant formulation and vaccination protocols were performed as described previously
except that the route of vaccination was intraperitoneal [19]. This is the most common and
successful route of vaccination in terms of inducing protective immunity in B.malayi–rodent
models [17, 29–36]. The gerbils in antigen vaccinated groups received 25 μg of recombinant
protein in 0.1 ml of Tris Buffered Saline (TBS) formulated with 0.1 ml of 1:5 Rehydragel LV
(alum) in TBS (General Chemical, Parsippany, NJ, USA). Gerbils in the adjuvant control
groups received alum in TBS only. Gerbils were vaccinated intraperitoneally 3 times (V1, V2,
and V3) at 2 week intervals. Antigen-adjuvant formulation was same as above for concurrent
vaccinations of individual Bm-103 and Bm-RAL-2 antigens, but the gerbils in the vaccinated
groups received two separate injections of alum-formulated Bm-103 and alum-formulated Bm-
RAL-2 at different locations in the intraperitoneal cavity; gerbils in the adjuvant control group
received equivalent amount of alum alone. Hence, the gerbils vaccinated with two antigens
(concurrent) and their adjuvant controls received twice the amount of alum as the gerbils vac-
cinated with only one of the antigens. Two weeks after the third vaccination (Post-V3), all
Table 1. Vaccination experiments conducted with Brugia malayi (Bm) recombinant proteinsBm-RAL-
2, Bm-103, the Bm-103—Bm-RAL-2 fusion protein and with Bm-103 + Bm-RAL-2 concurrently.
Experiment Number Vaccine Necropsy—days post-infection (dpi)
1 Bm-RAL-2 42
2 Bm-103 42
3 Bm-RAL-2 120
4 Bm-103 120
5 Bm-RAL-2; Bm-103 150
6 Bm-RAL-2 + Bm-103 (Concurrent) 90
7 Bm-RAL-2—Bm-103 (Fusion) 90
8 Concurrent; Fusion 90
9 Concurrent; Fusion 150
doi:10.1371/journal.pntd.0004586.t001
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gerbils were challenged with 100 B.malayi L3 larvae subcutaneously in the medial surface of
the left thigh.
A summary of the experiments conducted is shown in Table 1. In experiments 1 and 2, we
tested the vaccine efficacy of Bm-RAL-2 and Bm-103 individually, respectively, and the necrop-
sies were performed at 42 dpi. Necropsy at 42 dpi allowed for recovery of adult worms in a
short period of time. Experiments 3 and 4 were similar to experiments 1 and 2, respectively,
except the necropsies were performed at 120 dpi. This time point allowed a much easier recov-
ery of the adult worms due to their increased size. In experiment 5, the vaccine efficacy of Bm-
RAL-2 and Bm-103 was tested in parallel in a single experiment using the same adjuvant con-
trol group while the necropsies were performed at 150 dpi. Necropsies at 150 dpi also allowed
for studying the effect of vaccination on microfilariae levels in gerbil blood, and on embryogen-
esis in the fertile female worms. In experiment 6, we tested the vaccine efficacy of concurrent
vaccination with Bm-RAL-2 and Bm-103 and the necropsies were performed at 90 dpi. Experi-
ment 7 tested the vaccine efficacy of Bm-RAL-2—Bm-103 fusion protein and necropsies were
performed at 90 dpi. Experiment 6 and 7 were repeated together in experiment 8. Experiment
9 was similar to experiment 8 except that the necropsies were performed at 150 dpi, and the
embryogenesis in the surviving female worms was studied using the embryogram method.
Necropsies were performed as previously described [37]. Adult worms were collected from
the heart and lungs, right and left spermatic cord lymphatics, right and left testes and other
lymphoid organs including the right and left popliteal lymph nodes, right and left renal lymph
nodes, ilio-lumbar vessels, right and left sub-inguinal and iliac lymph nodes and vessels and
the peritoneal cavity. Worm recoveries were also examined by site of recovery and therefore
the distribution of worms in various organs was also recorded. Worms recovered from the
spermatic cord, testes and lymph nodes were grouped as lymphatic organ worms, and worms
recovered from the heart and lungs were grouped as heart and lungs worms. The worms recov-
ered from viscera/body cavity were not assigned to either of these two groups, as their site of
origin was unknown. The worm recovery data for heart & lungs and lymphatics tissue is pre-
sented as mean ± SD of worms within the organs. Additionally, the female: male ratio was cal-
culated for each experiment to determine whether the vaccination with Bm-RAL-2, Bm-103,
fusion protein, or concurrent vaccine affected male and female worms differently.
Measurement of total IgG response by ELISA
Antigen-specific IgG responses to the each of the corresponding recombinant protein were mea-
sured in sera collected after third vaccination (post-V3) and prior to challenge infection using
ELISA and following a protocol described previously [36]. ELISA plates were coated with recom-
binant Bm-RAL-2, Bm-103 or Bm-RAL-2—Bm-103 fusion protein and were tested with sera of
the individual gerbils vaccinated with the respective antigens. Bm-RAL-2, Bm-103 and Bm-RAL-2
—Bm-103 fusion protein coated plates were also tested with serum collected from gerbils immu-
nized with Bm-RAL-2 + Bm-103 concurrently. The endpoint titers were calculated as the serum
dilution from experimentally vaccinated animals that had an O.D. reading of 0.06 which is the O.
D. recorded for highest control serum dilution (1:1000). Serial dilutions of gerbil serum were
made and total antigen-specific IgG responses are reported as median with 25% and 75% percen-
tile of endpoint titers of the group because of few extreme outliers in the data set and the median
expresses a better middle value (central tendency) in a set of data than the mean/average.
Embryogram and microfilariae count
To study the effect of vaccination on embryogenesis, embryograms were performed on the sur-
viving female worms to enumerate the developing embryonic stages in utero (eggs, embryos,
Vaccine Efficacy of Bm-103 and Bm-RAL-2
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developing microfilariae and stretched microfilariae) as described previously [36]. Adult female
worms recovered 150 dpi (Experiments 5 and 9) were used for this purpose. Additionally, in
experiment 5 and 9, the number of circulating microfilariae in 500 μl of peripheral blood of
individual gerbils at the time of necropsy was determined using a Knott’s assay [38], [39].
In vitro larval killing assay
An L3 in vitro killing assay was performed as described previously [36] with slight modifica-
tions. Pooled sera from gerbils immunized with Bm-RAL-2, Bm-103, Bm-RAL-2—Bm-103
fusion or Bm-RAL-2 + Bm-103 were used in the assay. Based on availability of sufficient quan-
tities of sera, only the sera samples collected post V2 were used in the in vitro killing assay
using 1:20 dilution of serum and 2 x 105 thioglycolate stimulated peritoneal exudate cells
(PEC) from naïve gerbils. Performed in quadruplicate, 20 B.malayi L3s were cultured under
different treatment conditions and their survival was scored based on motility and morphology
at 48 hrs post-treatment. Worms that were completely immotile with granulated and disrupted
internal tissues were considered dead. The treatment groups were as follows: RPMI media con-
trol; PEC only; pre-immune serum with PEC; alum serum with PEC; anti-Bm-RAL-2 serum
alone; anti-Bm-103 serum alone; anti-(Bm-RAL-2—Bm-103) serum alone; and anti-(Bm-RAL-
2 + Bm-103) serum alone; anti-Bm-RAL-2 serum with PEC; anti-Bm-103 serum with PEC;
anti-(Bm-RAL-2—Bm-103) serum with PEC; and anti-(Bm-RAL-2 + Bm-103) serum with
PEC.
Statistics
All the vaccination experiments consisted of 10 gerbils per group and the statistical significance
between antigen-vaccinated gerbils and alum only controls were analyzed by Mann-Whitney
U test using GraphPad Prism 6 (GraphPad Software, San Diego, California USA). Protective
immunity induced by vaccination was determined by two metrics, percentage worm burden
reduction and host protection, as described earlier [19]. Percentage reduction was calculated
by subtracting the average number of worms recovered in antigen-vaccinated gerbils from the
average number of worms recovered from the control gerbils divided by average worms recov-
ered from the control gerbils, and then multiplied by 100. This metric is a measure of protec-
tion efficacy in a vaccine group based on worm recovery. Host protection determines what
percent of the vaccinees within the vaccination group benefited from the vaccination and had
less worm burden than the control group. Statistical analysis of host protection was performed
using bootstrap analysis. The bootstrap sample mean was estimated based on the worm burden
below the lower boundary of the 95% confidence interval of the control group (Host Protec-
tion). Then a kernel density estimate of the vaccine group (N = 10) was calculated and the per-
centage below the bootstrap 95% confidence interval was calculated. The R package "boot" was
used for the analysis [40–42].
Results
Vaccination with Bm-RAL-2 and Bm-103 individually, concurrently or as
a fusion protein induces protective immunity against B.malayi infection
in Mongolian gerbils
A summary of the results of all the performed experiments is presented in Table 2. Detailed
data from selected experiments are shown in each category and described below (Fig 2).
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Vaccination with Bm-RAL-2
In experiment 1, gerbils were vaccinated with E. coli expressed recombinant Bm-RAL-2 formu-
lated with alum and then challenged subcutaneously with 100 B.malayi L3s. To more quickly
investigate the effect of vaccination, necropsy was performed 42 dpi. Bm-RAL-2 induced 42%
reduction in worm burden and a 59% host protection when compared with alum control (Fig
2A). The effect of vaccination with Bm-RAL-2 on long-term (120 and 150 dpi) B.malayi infec-
tion in gerbils was 22% and 46% reduction of worm burden and 46% and 77% host protection,
respectively, when compared to alum controls (Table 2). The worm reduction of 46% at 150
dpi was statistically significant when compared with alum controls.
Vaccination with Bm-103
Experiment 2 was similar to experiment 1 except that a P. pastori expressed recombinant Bm-
103 protein was used. Vaccination with alum-formulated Bm-103 induced a significant worm
burden reduction of 39%, and a 75% of host protection when compared with the alum control
group (Fig 2B). The effect of vaccination with Bm-103 on long-term (120 and 150 dpi) B.
malayi infection of gerbils was a 34% and 22% reduction of worm burden and 69% and 50%
host protection, respectively, when compared to alum controls (Table 2).
Vaccination with Bm-103 and Bm-RAL-2 concurrently or as fusion
protein
In experiments 6–9, we tested the hypothesis that vaccination with Bm-RAL-2 and Bm-103
concurrently or as a fusion protein would enhance protection. Vaccination with Bm-RAL-2 +
Bm-103 concurrently induced a significant reduction of 56–61% in worm burden and a host
protection of 76–78% when compared with alum control groups (90 dpi) (Table 2). Vaccina-
tion with the fusion protein induced a significant 49–51% reduction in worm burden and a
Table 2. Vaccine efficacy, percentage reduction in worm recovery and host protection induced by vaccination of gerbils with Bm-RAL-2 and Bm-
103 individually, concurrently or as a fusion protein.
Vaccine Experiment Number Necropsy dpi % Reductiona P value % Host Protectionb
Bm-RAL-2 1 42 42 0.0880 59
3 120 22 0.3826 46
5 150 46 0.0131 77
Bm-103 2 42 39 0.0177 75
4 120 34 0.0366 69
5 150 22 0.3229 50
Concurrent 6 90 61 0.0072 76
8 90 56 0.0120 78
9 150 42 0.0272 75
Fusion 7 90 51 0.0398 66
8 90 49 0.0453 69
9 150 61 0.0053 80
a, Percentage reduction in worm burden was calculated as follows: % reduction = (average number of worms surviving in control group–average number
of worm surviving in vaccinated group)/average number of worm surviving in control group) × 100.
b, Bootstrap analysis of host protection. The measure of host protection determines the percentage of vaccinees within the vaccinated group beneﬁted
from the vaccination (worm burden below the lower boundary of the 95% conﬁdence interval).
doi:10.1371/journal.pntd.0004586.t002
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host protection of 66–69% when compared with alum control groups (90 dpi). A detailed out-
come of experiment 8 is illustrated in Fig 2C.
Experiment 9 was a repeat of experiment 8 except that the necropsy was performed at 150
dpi. In comparison to alum controls, vaccination with Bm-RAL-2 + Bm-103 concurrently and
as a fusion protein induced a significant reduction in worm burdens of 42% and 61% respec-
tively, and conferred a host protection of 75% and 80%, respectively (Fig 2D, Table 2).
When the distribution patterns of the recovered worms in the heart & lungs and in the lym-
phatic organs was compared between the vaccinated and the alum control groups it appeared
that in most cases the reduction in worm burden was not statistically significant in the separate
organs, indicating that the homing of the surviving worms had not been specifically impacted
by the vaccine as previously shown when gerbils were vaccinated with Bm-CPI-1 and Bm-CPI-
2 (37). The impact of the vaccines was reduction in the total number of worms recovered
regardless of where they were recovered from (S1 Table). In few of the experiments
Fig 2. Effect of vaccination withBm-RAL-2 andBm-103 individually, concurrently and as a fusion protein on the development of protective
immunity manifested as% reduction in worm burdens and% host protection against infection with Brugia malayi L3s in Mongolian gerbils. (A)
Vaccination with Bm-RAL-2 (42 dpi); (B) Vaccination with Bm-103 (42 dpi); (C) Vaccination with Bm-RAL-2—Bm-103 fusion protein or with Bm-RAL-2 + Bm-
103 concurrently (90 dpi); (D) Vaccination with Bm-RAL-2—Bm-103 fusion protein or Bm-RAL-2 + Bm-103 concurrently (150 dpi). Each dot represents the
total number of adult worms recovered from an individual animal. The lines represent mean with standard deviation. P 0.05 denotes a statistically
significant difference in total worm recovery (percent reduction) between vaccinated and alum control group, Mann–Whitney U Test, GraphPad Prism 6.
doi:10.1371/journal.pntd.0004586.g002
Vaccine Efficacy of Bm-103 and Bm-RAL-2
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004586 April 5, 2016 10 / 26
(Experiment 5, Bm-RAL-2; Experiment 6, concurrent vaccination; and Experiment 9, vacci-
nated with a fusion protein) in which a significant reduction of worm burden in a defined ana-
tomical location was observed, it was not reproduced in the repeated experiments, and
therefore might have arisen accidentally (S1 Table).
The female: male ratio data of all the experiments is shown in S2 Dataset (Fig S1 –S9 in S2
Dataset). The female: male ratio was between 0.81 and 1.65 in alum control groups of gerbils.
The ratio was not significantly different in Bm-RAL-2 vaccinated gerbils. In 2 of 3 Bm-103 vac-
cination experiments the female: male ratio was significantly greater than alum controls (Fig
S4 and S5 in S2 Dataset, P = 0.0094 and P = 0.0337). Vaccination with either the fusion protein
or both proteins in a concurrent vaccination did not alter the female: male ratio.
IgG responses induced by vaccination with Bm-RAL-2 and Bm-103
individually, concurrently or as a fusion protein
The antigen-specific IgG endpoint titers in animals vaccinated three times with Bm-RAL-2 and
Bm-103 individually, concurrently or as a fusion protein are shown in Fig 3 and in Table 3. Fig
3 shows endpoint titers in each vaccinated gerbil within the group whereas Table 3 specifically
shows the median with 25% and 75% percentile for the vaccinated group. Vaccination with all
the vaccine antigens and their combinations elicited strong antigen-specific IgG responses to
the corresponding antigens. The antibody data presented in Fig 3 and Table 3 are from experi-
ments terminated 150 dpi (Experiments 5 and 9) and are representative of all the other experi-
ments. The IgG endpoint titers in animals vaccinated with Bm-RAL-2 were significantly and 4
times higher than that in animals vaccinated with Bm-103 (P = 0.0022). In gerbils vaccinated
with Bm-RAL-2 + Bm-103 concurrently, the Bm-RAL-2-specific IgG endpoint titer was higher
than that of anti-Bm-103, though this was not statistically significant (P = 0.1184). Interest-
ingly, when the serum from animals vaccinated with Bm-RAL-2 + Bm-103 were tested against
the Bm-RAL-2—Bm-103 fusion protein, the IgG endpoint titer was significantly and 4 or 8
times higher than those specific to the individual antigens, Bm-RAL-2 or Bm-103, respectively
(P = 0.0094 and P = 0.0004). Serum from animals vaccinated with the fusion protein also
reacted with the individual antigens, Bm-RAL-2 and Bm-103; with the Bm-RAL-2-specific IgG
endpoint titer being significantly and 4 times higher than that of anti-Bm-103 (P< 0.0001).
The IgG endpoint titers against the fusion protein were also significantly and 8 times higher
than those of the anti-Bm-103 (P = 0.0001), but not of those of anti-Bm-RAL-2 (P = 0.3034).
To determine if any difference in antibody levels among the vaccinated gerbils had an effect on
worm recovery in each of the gerbils, a correlation analysis of antibody levels and worm numbers
was performed using the antigen-specific optical density obtained at 1:32,000. This dilution was
chosen because the magnitude of difference in antibody levels was highest at this dilution between
gerbils with high and low antibody titer. No significant relationships were detected between the
antibody titers of individual gerbils vaccinated with Bm-103, Bm-RAL-2 + Bm-103 concurrently or
as a fusion protein and the number of worms recovered from those individual animals. However,
there was a correlation between higher antibody titers to Bm-RAL-2 in Bm-RAL-2 vaccinated ger-
bils and higher worm recoveries in those animals (Table 4). Nonetheless, even in this group the
antibody titers did not correlate with the reduced number of worms recovered and protection.
Effect of vaccination with Bm-103 and Bm-RAL-2 individually,
concurrently or as a fusion protein on circulating microfilariae and
embryogenesis in female worms
To measure the levels of microfilariae in the blood, as well as to examine fertility of the surviv-
ing female worms, necropsies of gerbils vaccinated with Bm-103 and Bm-RAL-2 individually,
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Fig 3. Total IgG endpoint titers specific to Bm-103, Bm-RAL-2 or the fusion protein in gerbils vaccinated (N = 10) with Bm-RAL-2 and Bm-103
individually, concurrently or as a fusion protein. Each dot represents IgG endpoint titer from an individual animal. The lines represent median with
maximum and minimum range. Asterisk/s denotes a statistically significant difference in IgG endpoint titers between analyzed groups, Mann–Whitney U
Test, GraphPad Prism 6 (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001).
doi:10.1371/journal.pntd.0004586.g003
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concurrently or as fusion protein were performed at 150 dpi. Although there was a reduction
in microfilariae counts in the gerbils vaccinated with alum-formulated Bm-103, the percent
reduction was not statistically significant when compared with alum control groups (56%,
P = 0.2561; Fig S1 in S3 Dataset). However, there was a significant reduction in microfilariae
counts in gerbils vaccinated with alum-formulated Bm-RAL-2 (63%, P = 0.0410; Fig S1 in S3
Dataset). When embryograms were performed on the recovered female worms in vaccinated
gerbils and the alum control, it appeared that in Bm-103 vaccinated gerbils there was no signifi-
cant difference in the number of eggs, embryos and the total embryonic stages in the female
worms (Fig 4A–4C). In Bm-RAL-2 vaccinated gerbils, however, there was a substantial reduc-
tion (P = 0.0573) in the total embryonic developmental stages within the female worms col-
lected from Bm-RAL-2 vaccinated animals when compared with the alum control (Fig 4A–
4C), which possibly explains the significant decrease in the microfilariae in the blood seen in
this group.
Notably, although the microfilariae levels in gerbils vaccinated with Bm-103 + Bm-RAL-2
concurrently or as a fusion protein 150 dpi were similar to those found in the control groups
(Concurrent vs control, P = 0.1708; fusion vs control, P = 0.1834; Fig S2 in S3 Dataset), the
Table 3. IgG endpoint titers in gerbils vaccinated with Bm-RAL-2 and Bm-103 individually, concurrently or as a fusion protein at 2 weeks after 3rd
vaccination (experiments 5 and 9).
Vaccinating Antigen Antigen-speciﬁc endpoint titers
Median
(25%; 75% Percentile)
Bm-RAL-2 Bm-103 Fusion protein
Bm-RAL-2 2,048,000
(2,048,000; 4,096,000)
Bm-103 1,024,000
(896,000; 1,280,000)
Fusion 16,380,000 1,024,000 16,380,000
(8,192,000;16,380,000) (1,024,000;2048,000) (16,380,000;16,380,000)
Concurrent 2,048,000 1,024,000 6,144,000
(896,000; 2,560,000) (512,000; 1,280,000) (2,048,000; 16,380,000)
doi:10.1371/journal.pntd.0004586.t003
Table 4. Correlation analysis between antibody levels and worm recovery.
Vaccinating Antigen Correlation analysis between antibody levels
and worm recovery
R Value P Value
Bm-RAL-2 0.6441 0.0444
Bm-103 -0.1135 0.7548
Fusion 0.1226 0.7359
Concurrent 0.1002a 0.7838
0.2670b 0.4558
a Correlation analysis between IgG titers to Bm-RAL-2 and worm recovery in Bm-RAL-2 + Bm-103
concurrently vaccinated gerbils.
b Correlation analysis for IgG titers to Bm-103 and worm recovery in Bm-RAL-2 + Bm-103 concurrently
vaccinated gerbils.
doi:10.1371/journal.pntd.0004586.t004
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embryogram data showed a significant reduction in eggs, embryos and the total embryonic
stages within the female worms recovered from the vaccinated gerbils when compared with the
alum control groups (Fig 5A–5C).
In vitro killing assay
B.malayi L3 were cultured in the presence of PEC with or without serum from animals vacci-
nated with Bm-103 and Bm-RAL-2 individually, concurrently or as a fusion protein. Pre-
immune serum or serum from alum control groups served as the control sera. L3 survival was
scored 48 hrs post-treatment and the results are presented in Table 5. All the L3 survived in the
control serum groups including sera from vaccinated groups without PEC. In comparison, a
small but consistent killing was observed when the L3 were cultured in the presence of PEC
and anti-Bm-103 serum (31%) or with anti-Bm-RAL-2 serum (15%). Serum from gerbils vacci-
nated with Bm-RAL-2 + Bm-103 concurrently or with the fusion protein induced killing of 16
and 20%, respectively (Table 5). Only the L3s that were completely immotile with severely
granulated and disrupted internal tissues were considered as dead and the slow moving larvae
with PEC attached to its surface were not scored as dead worms. Hence, a stringent scoring sys-
tem was used to evaluate the killing assay, which might account for the reduced percentage of
L3 killing reported in this study. Irrespectively, overall more L3s were affected by PEC plus
antigen-specific serum. To illustrate the in vitro killing, a video clip of B.malayi L3 cultured in
Fig 4. Embryogram data of B.malayi female worms recovered 150 dpi from alum control,Bm-RAL-2 andBm-103 vaccinated gerbils. (A) Eggs/
female worm; (B) Embryos/female worm; (C) Total embryonic stages/female worm. Statistical significance was determined by Mann–Whitney U Test using
GraphPad Prism version 6, P 0.05. The line represents mean with standard deviation.
doi:10.1371/journal.pntd.0004586.g004
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the presence of alum serum and PEC (S1 Video) and a video clip of B.malayi L3 cultured in
the presence of anti-Bm-103 serum and PEC (S2 Video) are presented as supporting data. In
Fig 5. Embryogram data of B.malayi female worms recovered 150 dpi from alum control,Bm-103 + Bm-RAL-2 and Bm-103—Bm-RAL-2 vaccinated
gerbils. (A) Eggs/female worm; (B) Embryos/female worm; (C) Total embryonic stages/female worm. Statistical significance was determined by Mann–
Whitney U Test using GraphPad Prism version 6, asterisks denotes a significant difference between the alum control and the vaccinated group, P 0.05.
The line represents mean with standard deviation.
doi:10.1371/journal.pntd.0004586.g005
Table 5. Brugia malayi L3 larvae in vitro killing assays.
Treatment Percentage of L3 killing (%)
Media Control 0
PEC alone 0
Pre-immune serum + PEC 0
Alum serum + PEC 0
Anti-Bm-RAL-2 serum 0
Anti-Bm-103 serum 0
Anti-(Bm-RAL-2—Bm-103) serum 0
Anti-(Bm-RAL-2 + Bm-103) serum 0
Anti-Bm-RAL-2 serum + PEC 15
Anti-Bm-103 serum + PEC 31
Anti-(Bm-RAL-2—Bm-103) serum + PEC 20
Anti-(Bm-RAL-2 + Bm-103) serum + PEC 16
PEC, peritoneal exudate cells (Mongolian gerbils).
doi:10.1371/journal.pntd.0004586.t005
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the future, we might adopt a less stringent approach that also counts the partially non-motile
larvae as dead if cells are highly adhered to their surface and as shown in S2 Video.
Discussion
Previous studies have shown that protective immunity against Brugia spp is readily induced by
irradiated Brugia L3 in Rhesus monkeys [43], cats [44] and gerbils [45]. In addition, a wide
variety of recombinant proteins of B.malayi have also been shown to provide some degree of
protection ranging from 40% to 95% in worm burden reduction in various animal models
(some reviewed by Morris et al., 2013 [19, 29–36]). However, the current data is the first report
to demonstrate that alum-formulated Bm-103 or Bm-RAL-2 individually, concurrently or as a
fusion protein induce significant protection against a subcutaneous Brugia L3 challenge infec-
tion that resembles the course of infection in humans [46]. The range of protection seen in the
current study is consistent with previous reports of vaccination with other recombinant Brugia
proteins, even though the studies vary in many ways including the character of the antigen, the
adjuvant, the route of immunization, the route of challenge and the animal model used. A
majority of the other vaccination experiments were performed using the mouse-diffusion
chamber model or intraperitoneal infection (IP) of gerbils or southern multimammate mouse
with B.malayi L3 [17], [31], [47–52]. Moreover, in most cases, the vaccination experiments
were also not repeated to confirm consistency in inducing protective immunity by the vaccine
candidates tested. Very few investigators [30], [32], [53] have used the subcutaneous route of
infection of gerbils with B.malayi L3 as we report in the current study. This model more closely
mimics the natural infection pattern in humans and is a more critical test for substantiating
that the host protective immune response to such a challenge infection can be reproduced in
humans. In this system L3s, the other larval stages and early adult stages must migrate through
various connective tissues and locate suitable sites for development in the lymphatic system
and the blood vascular system [46], [54]; all these stages may be targets of protective immunity
as well [55]. Moreover, in this infection system, the adult stages mature and produce patent
infections (microfilariae in the blood) allowing the measurement of the impact vaccination has
on microfilariae burden as well, either through enumeration of circulating microfilariae in the
blood or by measuring the embryonic development within the surviving fertile adult female
worms by the embryogram assay [36]. The subcutaneous route of infection of gerbils with B.
malayi L3 also induces a down regulation of the inflammatory and immune responses in the
more chronic time of infection [56]. This state can be induced by all stages of the life cycle [57],
and is correlated with the level of microfilaremia [58]. This condition mimics the microfilare-
mic-hypo-responsive state seen in human lymphatic filariasis [59]. Notably, in situations
where the vaccination is protective but incomplete, as it is in most the cases, the surviving para-
sites might be capable of inducing a down regulation of the immune and inflammatory
response [60], which may alter subsequent protective immune responses potentially complicat-
ing the model but also mimicking the natural situation, adding to the model’s value. Future
experiments using an optimized vaccine could test this assumption experimentally in this ger-
bil infection model.
The objective of the present study was to test the efficacy of the B.malayi Bm-RAL-2 and
Bm-103 proteins that are the homologs of two confirmed vaccine candidates of O. volvulus,
Ov-RAL-2 and Ov-103. To this end, repeated vaccination experiments in the gerbil model were
done to determine efficacy at different time points post infection. Additionally, the protective
efficacy of administering Bm-RAL-2 and Bm-103 concurrently or as a fusion protein was tested
at 90 and 150 dpi.
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As was shown in the O. volvulus in mouse model [19], Bm-RAL-2 and Bm-103 repeatedly
induced protection against B.malayi infection in gerbils. Vaccination with Bm-RAL-2 and
Bm-103 induced protection ranging from 22–46% and 22–39%, respectively (Table 2). Vacci-
nation with Bm-RAL-2 and Bm-103 concurrently and as a fusion protein induced a more con-
sistent significant protective efficacy ranging from 42–61% and 49–61%, respectively (Table 2).
It is important to note that while vaccination with the fusion protein or concurrently consis-
tently resulted in a greater level of protection than when gerbils were vaccinated with the indi-
vidual antigen, it was not possible to statistically compare these data because they were not
directly compared in single experiments. Previously, enhanced level of protective immunity
induced by a multivalent protein vaccine has also been demonstrated against B.malayi [35],
[61–64]. However, increased levels of protection were not seen using similar bivalent immuni-
zations with the homologous proteins in the O. volvulusmouse chamber model, which only
can observe the effects of a vaccine on the development of L3 to L4 [19]. This further supports
the advantage of testing the O. volvulus homologous proteins in the B.malayi gerbil model that
allows enumerating the worm burden and effects on embryonic development in multiple ways.
For example, analyses of female: male ratio were performed to investigate if the vaccination
affected female and male worm survival differently. Vaccination with Bm-RAL-2, Bm-RAL-2
—Bm-103 fusion protein or Bm-RAL-2 and Bm-103 concurrently did not have a significant
impact on female: male ratio. These findings are consistent with a previous report where vacci-
nation with irradiated L3 of Acanthocheilonema viteae and subsequent challenge with A. viteae
L3 did not have an impact on female:male worm ratio in 3 different rodent hosts, gerbils, multi-
mammate rats and golden hamsters [65]. However, vaccination with Bm-103 resulted in signif-
icantly higher female: male ratio in 2 out of the 3 experiments, suggesting that vaccination with
Bm-103 might have affected male worms more than the female worms. It is unclear why this
small but significant difference in male and female susceptibility to vaccination should occur. It
did not occur in the gerbils vaccinated with the fusion protein or in concurrently vaccinated
gerbils when Bm-103 was part of these vaccinations. It is possible that there is a differential
expression of these proteins in both sexes and/or in different tissues but there is no evidence
for this. Irrespective, there were other effects on the surviving female worms; reduced produc-
tion of microfilariae and/or embryonic development within the worms.
One of the methods to measure fertility of female worms is to count the circulating microfi-
lariae in the blood of vaccinated or adjuvant control gerbils. When compared with alum con-
trol groups, a significant reduction in MF was observed in gerbils vaccinated with Bm-RAL-2,
whereas gerbils vaccinated with Bm-103, Bm-RAL-2—Bm-103 fusion protein or concurrently
were not significantly different (Fig S1 –S2 in S3 Dataset). The reason for not being able to
observe significant differences in levels of circulating MF in vaccinated vs. alum control groups
could be related to the early time point that was chosen for necropsy (i.e. 150 dpi). The present
experiments were more focused on measuring the efficacy of the vaccines against the develop-
ment of the infections to the adult stages and this time point served this purpose well. In an
independent project, we performed MF counts in B.malayi infected gerbils at different time
points over the course of 3 years; higher levels of MF started to appear only after 200 dpi,
which reached peak levels at 300 dpi (Fig S3 in S3 Dataset). Hence, long-term experiments in
which we extend the necropsies to 300 dpi, when higher levels of MF are expected in the con-
trol groups, will allow us to determine the direct effect of vaccination with Bm-RAL-2 and Bm-
103 as a fusion protein or co-administered concurrently on MF production in vivo. We plan to
perform such experiments in the future. Regardless, necropsies at 150 dpi allowed us to con-
duct the embryogram assays in the surviving female worms, which gave us indirect data on the
MF development. This demonstrated that although vaccination with Bm- RAL-2 and Bm-103
individually did not severely affect the fecundity of the surviving female worms, their fecundity
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was significantly reduced in gerbils vaccinated with Bm- RAL-2 and Bm-103 concurrently or as
a fusion protein. Thus, vaccination with Bm- RAL-2 and Bm-103 concurrently or as a fusion
protein induced significant levels of protection against a subcutaneous infection of Mongolian
gerbils reducing the total worm burden as well as the fecundity of remaining surviving female
worms by significantly reducing the numbers of eggs, embryos, and total embryonic stages
within the female worms (Fig 4). Such an anti-fecundity effect of a vaccine may also support
the reduction of circulating microfilariae in the endemic areas and thus hasten the interruption
of transmission presently done only by MDA with drugs and thus meet the disease elimination
targets. Mathematical modeling studies are underway to evaluate the impact that vaccination
with a bi-valent vaccine administered concurrently or a fusion protein has on blocking trans-
mission in areas where MDA is implemented [66].
The mechanism by which the immunity induced by the Bm- RAL-2 and Bm-103 adminis-
tered concurrently or as a fusion protein affects embryogenesis in female worms is unknown. It
may be related to the disruption of an unknown role of the proteins during embryogenesis.
Interestingly, in both B.malayi and O. volvulus, both proteins are also expressed on the surface
of microfilariae (Fig S2 and Fig S4 in S1 Dataset). O. volvulus antibodies against Ov-103 also
kill microfilariae in vitro in the presence of neutrophils [22]. Recently, we reported that vacci-
nation with a mutated B.malayi cysteine protease inhibitor (Bm-CPI-2M) also reduced the
fecundity of female worms [28]. In Caenorhabditis elegans, the homolog of Bm-CPI-2M, cyste-
ine protease inhibitor CPI-2a, was shown to have an essential regulatory role during oogenesis
and fertilization [67], which suggested that Bm-CPI-2 could also have similar roles during
embryogenesis in B.malayi. The functional properties of Bm-103 and Bm-RAL-2 are currently
unknown. It is also possible a general morbidity is induced in the vaccinated animals against
the female worms, which may be responsible for this effect. At this stage it is not possible to
address the specific role(s) these proteins have during embryogenesis of B.malayi or how
immunity induced by these vaccinations has reduced fecundity. Notably, vaccination can
reduce fecundity in other helminths in addition to worm burden, including the vaccination of
dogs with Ac-16, an immunodominant surface antigen from the hookworm Ancylostoma cani-
num that is a homolog of Ov-RAL-2 and Bm-RAL-2 [68–70].
In all of the vaccination experiments with Bm-RAL-2 and Bm-103 individually or as a fusion
protein or concurrently a strong antigen-specific IgG response to the corresponding antigens
was elicited. The responses against Bm-RAL-2 were always higher than those against Bm-103
regardless of if the protein was used for vaccination alone or in combination with Bm-103
when they were co-administered concurrently or as a fusion protein, pointing to the possibility
that Bm-RAL-2 is a much stronger immunogen. Additionally, antibodies elicited in gerbils
immunized with the fusion protein recognized both individual Bm-RAL-2 and Bm-103 recom-
binant proteins, suggesting that the expression of the Bm-RAL-2—Bm-103 fusion protein did
not alter the individual protein structures or their functional properties. Although vaccination
with alum-formulated Bm-RAL-2 or Bm-103 elicited strong antigen-specific IgG responses,
sera taken from chronically infected gerbil sera (150 dpi) did not recognize either Bm-103 or
Bm-RAL-2, suggesting that these proteins perhaps are not as highly immunogenic during a pri-
mary infection as other filarial proteins such as the B.malayi abundant larval transcript
[21,71]. Correlation analysis between the numbers of worms recovered and the antigen-specific
antibody endpoint titers in vaccinated gerbils did not show any specific relationship between
the titer and level of protection. Lack of significant correlations between antibody titers and the
number of worms recovered from the vaccinated gerbils is consistent with the previous report
that showed no relationship between endpoint tiers and efficacy of the Ov-RAL2 and Ov-103
vaccine antigens in the mouse model [19]. Nonetheless, we were able to show that the antibod-
ies could in part be functional and kill in vitro B.malayi L3 via the antibody mediated cell
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cytotoxicity (ADCC); antigen-specific serum in the presence of PEC induced killing of 15–30%
L3s. The reduced percentage of L3 killing we observed in this study might have been because
only the L3s that were completely immotile with severely granulated and disrupted internal tis-
sues were considered as dead; slow moving larvae with PEC attached to its surface were not
included as dead larvae. Hence a stringent scoring system was used to evaluate the killing
assay, although overall we observed more L3s were affected by PEC plus antigen specific
serum. Secondly, the sera used for in vitro killing assay was pooled sera after the second immu-
nization (post V2) as we did not have enough sera of post V3 for testing in these in vitro assays;
the antibody titers of sera post V2 was much lower than those post V3, which could have also
attributed to the reduced percentage of L3 killing observed.
We did not enumerate or examine the cytokine production from cells present in the circula-
tion or in the lymphoid system at the time of necropsy. These data will be more important and
informative if cells are collected at an earlier time points, during the migration of larval para-
sites which are the likely the major targets of the protective immune responses induced. Never-
theless, we did examine the recovered surviving adult worms with a compound microscope;
there was no adherence of cells or formation of granulomas around these adult worms, hence
there is no clear direct evidence that vaccination can impact adult worms directly. In previous
studies, the mechanism of protection induced by vaccination with irradiated L3 was resolved
and shown to be Th2 dependent (IL-4 and/or IL-5) with the essential involvement of IgE and
eosinophils against O. volvulus and B.malayi in mice [72–74], against B. pahangi in cats [75],
and against Litomosoides sigmodontis in mice [76–80]. The lack of immunological reagents
specific for gerbils complicates a detailed investigation of comprehensive immunological
responses elicited and functional in this animal model. In the past, the measurement of mRNA
expression levels of gerbil cytokine genes was used in other experimental system [81], and
could be useful in future studies to study the mechanism of protection induced by vaccination
with the protective recombinant proteins we studied here.
The protective immunity induced by vaccination with Bm-RAL-2 and Bm-103 individually
or as a fusion protein or when administered concurrently against B.malayi subcutaneous infec-
tion of gerbils supports the findings of Hess et al., 2014 [19] and confirms that these two anti-
gens are important vaccine candidates as they can also control adult worm burden and
fecundity of female worms in the gerbil-model, and thus could be used as additional control
tools against onchocerciasis and lymphatic filariasis. The fact that these homologous proteins
are effective in inducing protective immunity against two filarial nematodes and in two distinct
animal models offers a high probability for success at inducing protective immunity in humans
as well. Recently, The Onchocerciasis Vaccine for Africa (TOVA) initiative was launched with
the aim of developing a prophylactic vaccine for children under the age of five who do not
receive ivermectin; Ov-103 and Ov-RAL-2 are two vaccine candidates that meet the target
product profile of TOVA [4], [82].
In summation, although the vaccine efficacy of Bm-RAL-2 and Bm-103 is reproducible and
consistent, vaccination with Bm-RAL-2 and Bm-103 concurrently or as a fusion protein con-
ferred enhanced levels of protection against a subcutaneous B.malayi infection in Mongolian
gerbils. Specifically, our findings demonstrate that these vaccine candidates when combined
together not only induce in gerbils a significant reduction in the B.malayi adult worm burden
but it also reduced the fecundity of surviving female worms. Thus, testing of these vaccine can-
didates in two animal models, the O. volvulus- mouse-diffusion chamber model and the B.
malayi -Mongolian gerbil model have proven to be an efficient means to critically confirm the
potency of filarial vaccine candidates; vaccine candidates that work in both animal models
increase their probability of being protective in humans as well. Further investigation of these
vaccine candidates is warranted with work focusing towards product development and
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manufacturing of a bivalent vaccine. The ultimate goal of this program is the clinical develop-
ment and testing of a first-generation recombinant filarial vaccine.
Supporting Information
S1 Dataset. Fig S1 A. Sequence alignment of Bm-103 and Ov-103. Identical amino acid resi-
dues are shaded in black, and conservative substitutions are shaded in gray. The sequence iden-
tities between the two proteins are added at the end of sequence. Fig S1 B. Phylogenetic
analysis of Bm-103 (GenBank# XP_001891826.1) with other nematode homologues such as
Ov-103 (Onchocerca volvulus, AAA63412.2); Ll-103 (Loa loa, EJD74696.1);Wb-103 (Wucher-
eria bancrofti, EJW78103.1); Ay-103 (A. ceylanicum, EPB77163.1); Na-103 (Necator ameri-
canus, XP_013293822.1); Hc-103 (Haemonchus contortus, KHN78708.1); Ce-103
(Caenorhabditis elegans, NP_001023598.1), and Tc-103 (Toxocara canis, KHN78708.1). The
data represents neighbor-joining tree representing phylogenetic relationships between nema-
tode 103-like proteins. Fig S2. Immunoelectron microscopic localization of Ov-103 and Bm-
103 in female worms (♀), uterine microfilariae (MF) and L3s (insert shows the granules of the
glandular esophagus in L3) of O. volvulus and B.malayi, respectively. Abbreviations: hy–hypo-
dermis, cu–cuticle, mu–muscle; bar—500 nm. Fig S3 A. Sequence alignment of Bm-RAL-2 and
Ov-RAL-2. Identical amino acid residues are shaded in black, and conservative substitutions
are shaded in gray. The sequence identities between the two proteins are added at the end of
sequence. Fig S3 B. Phylogenetic analysis of Bm-RAL-2 (GenBank# XP_001900036.1) with
other nematode homologues such as Ov-RAL-2 (Onchocerca volvulus, # P36991.1);Wb-RAL-2
(Wuchereria bancrofti, AAC17637.1); Ll-RAL-2 (Loa loa, AAG09181.1); Al-16 (Ascaris lumbri-
coides, ADB45852.1); Tc-RAL-2 (Toxocara canis, KHN84076.1); As-16 (A. suum,
BAC66614.1); Ac16 (Ancylostoma caninum, ABD98404.1); As14 (A. suum, BAB67769.1); Ce-
RAL-2 (Caenorhabditis elegans, NP_495640.1); Na-SAA-2 (Necator americanus,
XP_013290850.1); Ay-RAL-2 (A. ceylanicum, EPB72254.1); Hc-RAL-2 (Haemonchus contor-
tus, CDJ91573.1), and Ad-RAL-2 (A. duodenale, KIH68079.1). The data represents neighbor-
joining tree representing phylogenetic relationships between nematode RAL-2-like proteins.
Fig S4. Immunoelectron microscopic localization of Ov-RAL-2 and Bm-RAL-2 in female
worms (♀), uterine microfilariae (MF) and L3s (insert shows the granules of the glandular
esophagus in L3) of O. volvulus and B.malayi, respectively. Abbreviations: hy–hypodermis,
cu–cuticle; bar—500 nm. Fig S5 Sequence alignment of Bm-103 –Bm-RAL-2 and Ov-103 –Ov-
RAL-2 fusion proteins. The amino acid sequence corresponding to 103 and RAL-2 are squared
in black and red, respectively. The linker is squared in blue. Identical amino acid residues are
shaded in black and conservative substitutions are shaded in gray. The sequence identities and
similarities between the two fusion proteins are added at the end of sequence.
(PPTX)
S2 Dataset. Fig S1. Experiment 1; Female: male ratio in gerbils vaccinated with Bm-RAL-2 (42
dpi). Each dot represents the total number of adult worms recovered from an individual ani-
mal. The lines represent mean with standard deviation. P 0.05 denotes a statistically signifi-
cant difference in total worm recovery (percent reduction) between vaccinated and alum
control group, Mann–Whitney U Test, GraphPad Prism 6. Fig S2. Experiment 1; Female: male
ratio in gerbils vaccinated with Bm-103 (42 dpi). Each dot represents the total number of adult
worms recovered from an individual animal. The lines represent mean with standard deviation.
P 0.05 denotes a statistically significant difference in total worm recovery (percent reduction)
between vaccinated and alum control group, Mann–Whitney U Test, GraphPad Prism 6. Fig
S3. Experiment 3; Female: male ratio in gerbils vaccinated with Bm-RAL-2 (120 dpi) Each dot
represents the total number of adult worms recovered from an individual animal. The lines
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represent mean with standard deviation. P 0.05 denotes a statistically significant difference
in total worm recovery (percent reduction) between vaccinated and alum control group,
Mann–Whitney U Test, GraphPad Prism 6. Fig S4. Experiment 4; Female: male ratio in gerbils
vaccinated with Bm-103 vaccination (120 dpi). Each dot represents the total number of adult
worms recovered from an individual animal. The lines represent mean with standard deviation.
P 0.05 denotes a statistically significant difference in total worm recovery (percent reduction)
between vaccinated and alum control group, Mann–Whitney U Test, GraphPad Prism 6. Fig
S5. Experiment 5; Female: male ratio in gerbils vaccinated with Bm-RAL-2 and Bm-103 (150
dpi). Each dot represents the total number of adult worms recovered from an individual ani-
mal. The lines represent mean with standard deviation. P 0.05 denotes a statistically signifi-
cant difference in total worm recovery (percent reduction) between vaccinated and alum
control group, Mann–Whitney U Test, GraphPad Prism 6. Fig S6. Experiment 6; Female: male
ratio in gerbils vaccinated with Bm-RAL-2 and Bm-103 concurrently (90 dpi). The lines repre-
sent mean with standard deviation. P 0.05 denotes a statistically significant difference in
total worm recovery (percent reduction) between vaccinated and alum control group, Mann–
Whitney U Test, GraphPad Prism 6. Fig S7. Experiment 7; Female: male ratio in gerbils vacci-
nated with Bm-RAL-2 and Bm-103 as a fusion antigen vaccination (90 dpi). The lines represent
mean with standard deviation. P 0.05 denotes a statistically significant difference in total
worm recovery (percent reduction) between vaccinated and alum control group, Mann–Whit-
ney U Test, GraphPad Prism 6. Fig S8. Experiment 8; Female: male ratio in gerbils vaccinated
with Bm-RAL-2 and Bm-103 as fusion protein and concurrently (90 dpi). The lines represent
mean with standard deviation. P 0.05 denotes a statistically significant difference in total
worm recovery (percent reduction) between vaccinated and alum control group, Mann–Whit-
ney U Test, GraphPad Prism 6. Fig S9. Experiment 9; Female: male ratio in gerbils vaccinated
with Bm-RAL-2 and Bm-103 as fusion protein and concurrently (150 dpi). The lines represent
mean with standard deviation. P 0.05 denotes a statistically significant difference in total
worm recovery (percent reduction) between vaccinated and alum control group, Mann–Whit-
ney U Test, GraphPad Prism 6.
(PPTX)
S3 Dataset. Fig S1. Experiment 5, microfilariae levels in alum controls and gerbils vaccinated
with Bm-103 and Bm-RAL-2 150 dpi. Statistical significance was determined by Mann–Whit-
ney U Test using GraphPad Prism version 6, asterisks denotes a significant difference between
alum controls and vaccinated group, P 0.05. The line represents mean with standard devia-
tion. Fig S2. Experiment 9, microfilariae levels in alum controls and gerbils vaccinated with
Bm-103 and Bm-RAL-2 fusion and concurrent vaccines 150 dpi. Statistical significance was
determined by Mann–Whitney U Test using GraphPad Prism version 6, asterisks denotes a
significant difference between alum controls and vaccinated group, P 0.05. The line repre-
sents mean with standard deviation. Fig S3. A survey of microfilariae (MF) levels in gerbils
infected with B.malayi over a period of 3 years. Gerbils were infected with 150 infective B.
malayi L3 larvae and gerbils were bled periodically and MF levels in 20 μl of gerbil blood were
enumerated under a light microscopy.
(PPTX)
S1 Table. Number of worms recovered from the lymphatics and from the heart & lungs of
gerbils vaccinated with Bm-RAL-2 and Bm-103 individually, concurrently or as a fusion
protein.
(DOCX)
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S1 Video. Control assay, L3 larvae cultured in the presence of serum from gerbils injected
with alum and peritoneal exudate cells (PEC).
(AVI)
S2 Video. In vitro killing of L3 larvae in the presence of anti-Bm-103 serum and peritoneal
exudate cells (PEC).
(AVI)
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